KK
TVTX icon

KLP Kapitalforvaltning’s Travere Therapeutics TVTX Stock Holding History

KLP Kapitalforvaltning’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$559K Buy
18,800
+800
+4% +$23.9K ﹤0.01% 1378
2025
Q4 		$688K Sell
18,000
-1,500
-8% -$48.8K ﹤0.01% 1245
2025
Q3 		$466K Hold
19,500
– – ﹤0.01% 1436
2025
Q2 		$289K Buy
19,500
+4,500
+30% +$74.6K ﹤0.01% 1615
2025
Q1 		$269K Hold
15,000
– – ﹤0.01% 1614
2024
Q4 		$261K Buy
+15,000
New +$265K ﹤0.01% 1705

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KLP Kapitalforvaltning's TVTX Position: Q1 2026 in Review

KLP Kapitalforvaltning increased its Travere Therapeutics (TVTX) stake by 4.4% in Q1 2026, buying an estimated $23.9K and bringing the position to 18,800 shares worth $559K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

KLP Kapitalforvaltning first reported a position in TVTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $688K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • KLP Kapitalforvaltning held 18,800 shares of Travere Therapeutics worth $559K as of Q1 2026.
  • KLP Kapitalforvaltning bought 800 Travere Therapeutics shares in Q1 2026, an estimated $23.9K.
  • Travere Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q1 2026, its #1378 holding.
  • KLP Kapitalforvaltning first reported a position in Travere Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • KLP Kapitalforvaltning's Travere Therapeutics position peaked at $688K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q1 2026, filed 29 Apr 2026.